Conversely, use of an ASNS inhibitor significantly restrained the growth and metastasis of RCC cells in vitro and in vivo. In summary, our findings highlighted the critical role of L-Asn in RCC and identified ASNS as a novel substrate for VHL-mediated ubiquitination, presenting a potential new target for RCC treatment.

2 days ago

Journal

AKT1 (V-akt murine thymoma viral oncogene homolog 1) • VHL (von Hippel-Lindau tumor suppressor) • ASNS (Asparagine synthetase)

VHL mutation

Primitive Neuroectodermal Kidney Tumor in Adults. A Systematic Review. (PubMed, Arch Esp Urol)

rPNET in adults is a rare, aggressive entity that is frequently diagnosed at an advanced stage. A multimodal strategy of surgery when feasible plus systemic multi-agent CT, with radiotherapy in selected cases, should be planned upfront in specialised centres by a multidisciplinary team.

2 days ago

Review • Journal

EWSR1 (EWS RNA Binding Protein 1) • CD99 (CD99 Molecule)

Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients (clinicaltrials.gov)

P=N/A, N=21081, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Mar 2026 --> Mar 2027

2 days ago

Trial completion date • Trial primary completion date

Pan-cancer analysis identifies FKBP10 as a regulator of tumor immunosuppression and therapeutic response. (PubMed, Transl Oncol)

FKBP10 is closely linked to tumor progression and treatment response by contributing to metabolic reprogramming, immunosuppressive microenvironment modulation, and programmed cell death regulation, supporting its potential as a biomarker and therapeutic target for predicting prognosis, treatment response, and immunotherapy outcomes.

5 days ago

Journal • IO biomarker • Pan tumor

FKBP10 (FKBP Prolyl Isomerase 10) • FKBP5 (FKBP Prolyl Isomerase 5)

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection (clinicaltrials.gov)

P=N/A, N=2000, Recruiting, Alliance for Clinical Trials in Oncology | Trial primary completion date: Jan 2026 --> Jan 2027

6 days ago

Trial primary completion date

MUC16 (Mucin 16, Cell Surface Associated)

Actuate 1801: 9-ING-41 in Patients With Advanced Cancers (clinicaltrials.gov)

P2, N=350, Active, not recruiting, Actuate Therapeutics Inc. | Trial completion date: Jan 2026 --> Jun 2026 | Trial primary completion date: Jan 2025 --> Jun 2026

6 days ago

Trial completion date • Trial primary completion date

BCL2 (B-cell CLL/lymphoma 2)

carboplatin • gemcitabine • albumin-bound paclitaxel • irinotecan • pegylated liposomal doxorubicin • lomustine • elraglusib (9-ING-41)

Improving the diagnosis of renal tumours of young people through integrated molecular analysis. (PubMed, J Cancer Res Clin Oncol)

We highlight that molecular analysis, particularly agnostic WGS, has a key routine role in the care of children with renal tumours. It is likely that outcomes for these young people have been improved through more accurate diagnosis and early detection of cancer predisposition.

6 days ago

Journal

ERC1 (ELKS/RAB6-Interacting/CAST Family Member 1)

Concurrent Tissue and Circulating Tumor DNA analysis in Renal Cell Carcinoma: Insights from a Multimodal Database. (PubMed, Oncologist)

ctDNA testing offers complementary insights to tissue NGS in RCC, particularly in metastatic disease, suggesting the potential utility of ctDNA in advanced RCC. Longitudinal analysis may enhance delineation of biomarkers of response and resistance at mutation and ctDNA fraction levels.

7 days ago

Journal • Circulating tumor DNA

TP53 (Tumor protein P53) • PBRM1 (Polybromo 1) • BAP1 (BRCA1 Associated Protein 1) • SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase)

Tempus xT Assay • Tempus xF Assay

A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK) (clinicaltrials.gov)

P1, N=35, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting | Initiation date: Jul 2026 --> Mar 2026

7 days ago

Enrollment open • Trial initiation date • First-in-human

Opdivo (nivolumab) • Yervoy (ipilimumab) • HC-7366

Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer (clinicaltrials.gov)

P1, N=62, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027

7 days ago

Trial completion date

MK-2206 • hydroxychloroquine